Literature DB >> 15539438

Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial.

K Oddsson1, B Leifels-Fischer, D Wiel-Masson, N R de Melo, C Benedetto, C H J Verhoeven, T O M Dieben.   

Abstract

BACKGROUND: This trial was conducted to compare cycle control with vaginal ring a combined contraceptive vaginal ring, and a combined oral contraceptive (COC) delivering 30 mug ethinylestradiol (EE) and 150 mug levonorgestrel.
METHODS: This open-label, randomized, multi-centre, Phase III study involved adult women from 11 countries. Subjects were treated with either vaginal ring or a COC for 13 cycles (12 months).
RESULTS: A total of 1030 subjects (vaginal ring, n=512; COC, n=518) comprised the intention-to-treat (ITT) population. The percentage of women in the ITT population who completed the trial was 70.9% for vaginal ring and 71.2% for the COC group. The incidence of breakthrough bleeding and spotting over cycles 2-13, the primary efficacy parameter, was lower with vaginal ring (range 2.0-6.4%) than the COC (range 3.5-12.6%), and for cycles 2 and 9 the lower incidence with vaginal ring was confirmed as statistically significant (P=0.003 and P=0.002 respectively). The incidence of intended bleeding was significantly higher over all cycles with vaginal ring (58.8-72.8%) than with the COC (43.4-57.9%).
CONCLUSIONS: Cycle control with vaginal ring was excellent and superior to that of a COC containing 30 mug EE.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15539438     DOI: 10.1093/humrep/deh604

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  6 in total

1.  Bleeding profile associated with 1-year use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system: pooled analysis from Phase 3 trials.

Authors:  Carolina Sales Vieira; Ian S Fraser; Marlena G Plagianos; Anne E Burke; Carolyn L Westhoff; Jeffrey Jensen; Vivian Brache; Luis Bahamondes; Ruth Merkatz; Regine Sitruk-Ware; Diana L Blithe
Journal:  Contraception       Date:  2019-08-06       Impact factor: 3.375

2.  Vaginal ring acceptability: A systematic review and meta-analysis of vaginal ring experiences from around the world.

Authors:  Kathleen Ridgeway; Elizabeth T Montgomery; Kevin Smith; Kristine Torjesen; Ariane van der Straten; Sharon L Achilles; Jennifer B Griffin
Journal:  Contraception       Date:  2021-10-10       Impact factor: 3.051

3.  Attitudes toward the vaginal ring and transdermal patch among adolescents and young women.

Authors:  Tina R Raine; Laura B Epstein; Cynthia C Harper; Beth A Brown; Cherrie B Boyer
Journal:  J Adolesc Health       Date:  2009-05-30       Impact factor: 5.012

Review 4.  Skin patch and vaginal ring versus combined oral contraceptives for contraception.

Authors:  Laureen M Lopez; David A Grimes; Maria F Gallo; Laurie L Stockton; Kenneth F Schulz
Journal:  Cochrane Database Syst Rev       Date:  2013-04-30

5.  Review of the combined contraceptive vaginal ring, NuvaRing.

Authors:  Frans Jme Roumen
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

6.  Efficacy of combined contraceptive vaginal ring versus oral contraceptive pills in achieving hypothalamic-pituitary-ovarian axis suppression in egg donor in vitro fertilization cycles.

Authors:  Robin Lynn Thomas; Lisa Marie Halvorson; Bruce Richard Carr; Kathleen Marie Doody; Kevin John Doody
Journal:  J Reprod Infertil       Date:  2013-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.